Published in PLoS Pathog on October 24, 2013
Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. MBio (2014) 1.15
The Role of the DNA Damage Response throughout the Papillomavirus Life Cycle. Viruses (2015) 0.89
The Deacetylase Sirtuin 1 Regulates Human Papillomavirus Replication by Modulating Histone Acetylation and Recruitment of DNA Damage Factors NBS1 and Rad51 to Viral Genomes. PLoS Pathog (2015) 0.82
Cancer-causing human papillomavirus E6 proteins display major differences in the phospho-regulation of their PDZ interactions. J Virol (2014) 0.81
Human Papillomavirus (HPV) Prevalence in Nasal and Antrochoanal Polyps and Association with Clinical Data. PLoS One (2015) 0.79
Human papillomavirus promotes Epstein-Barr virus maintenance and lytic reactivation in immortalized oral keratinocytes. Virology (2016) 0.79
Using Organotypic Epithelial Tissue Culture to Study the Human Papillomavirus Life Cycle. Curr Protoc Microbiol (2016) 0.75
Host cell restriction factors that limit transcription and replication of human papillomavirus. Virus Res (2016) 0.75
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem (1998) 28.13
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell (1990) 20.60
Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst (1995) 18.86
Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol (1999) 16.81
A review of human carcinogens--Part B: biological agents. Lancet Oncol (2009) 13.85
The global health burden of infection-associated cancers in the year 2002. Int J Cancer (2006) 13.57
The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell (1993) 12.41
Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature (1998) 7.81
DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev (1998) 7.78
Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein. Proc Natl Acad Sci U S A (1986) 7.78
Transient replication of BPV-1 requires two viral polypeptides encoded by the E1 and E2 open reading frames. EMBO J (1991) 6.00
A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J (1991) 5.39
Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated structure of the E6 and E7 gene products. J Mol Biol (1987) 5.13
Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature (2003) 4.80
The carcinogenicity of human papillomavirus types reflects viral evolution. Virology (2005) 4.72
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA (2007) 4.66
Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody. Radiat Res (2002) 4.05
Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature (1996) 3.61
Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins. Proc Natl Acad Sci U S A (1992) 3.58
Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell (1991) 3.58
Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol Cell Biol (1992) 3.37
Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci U S A (1997) 3.37
Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci U S A (1993) 3.32
Properties of a non-tumorigenic human cervical keratinocyte cell line. Int J Cancer (1989) 3.30
Regulation of p53 in response to DNA damage. Oncogene (1999) 3.23
Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms. J Virol (1989) 3.02
Papillomavirus polypeptides E6 and E7 are zinc-binding proteins. J Virol (1989) 3.01
The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J (1992) 2.97
Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation. J Virol (1991) 2.79
Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol Cell Biol (2000) 2.79
Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells. EMBO J (1987) 2.56
The biology and life-cycle of human papillomaviruses. Vaccine (2012) 2.53
Transient replication of bovine papilloma virus type 1 plasmids: cis and trans requirements. Proc Natl Acad Sci U S A (1986) 2.49
Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol (2000) 2.44
Transient replication of human papillomavirus DNAs. J Virol (1992) 2.43
Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA. J Virol (1997) 2.21
Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J Virol (1999) 2.09
Normal growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS. J Invest Dermatol (2000) 2.08
The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle. J Virol (2000) 2.05
Human papillomavirus type 31 oncoproteins E6 and E7 are required for the maintenance of episomes during the viral life cycle in normal human keratinocytes. Proc Natl Acad Sci U S A (1999) 2.00
The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J Virol (1994) 1.97
Robust production and passaging of infectious HPV in squamous epithelium of primary human keratinocytes. Genes Dev (2009) 1.97
Establishment of the human papillomavirus type 16 (HPV-16) life cycle in an immortalized human foreskin keratinocyte cell line. Virology (1999) 1.96
Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog (2009) 1.94
STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem (2003) 1.79
DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulation. Mol Biol Cell (2006) 1.78
MDMX regulation of p53 response to ribosomal stress. EMBO J (2006) 1.77
Transcriptional role of p53 in interferon-mediated antiviral immunity. J Exp Med (2008) 1.72
Papillomavirus E6 proteins. Virology (2008) 1.70
Life cycle heterogeneity in animal models of human papillomavirus-associated disease. J Virol (2002) 1.66
Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. EMBO J (1994) 1.64
Induction of human papillomavirus type 18 late gene expression and genomic amplification in organotypic cultures from transfected DNA templates. J Virol (1997) 1.59
Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle. J Virol (2003) 1.49
The papillomavirus E1 helicase activates a cellular DNA damage response in viral replication foci. J Virol (2011) 1.49
Interferon induces morphologic reversion with elimination of extrachromosomal viral genomes in bovine papillomavirus-transformed mouse cells. Proc Natl Acad Sci U S A (1982) 1.46
Human papillomaviruses recruit cellular DNA repair and homologous recombination factors to viral replication centers. J Virol (2012) 1.37
Human papillomavirus type 16 E1circumflexE4 contributes to multiple facets of the papillomavirus life cycle. J Virol (2005) 1.32
Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response. Proc Natl Acad Sci U S A (2006) 1.31
Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene (1999) 1.30
Replication and partitioning of papillomavirus genomes. Adv Virus Res (2008) 1.21
Transcriptional repression by the C-terminal domain of p53. Oncogene (1995) 1.20
Genetic analysis of high-risk e6 in episomal maintenance of human papillomavirus genomes in primary human keratinocytes. J Virol (2002) 1.19
High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J Virol (2011) 1.16
Role of the E1--E4 protein in the differentiation-dependent life cycle of human papillomavirus type 31. J Virol (2005) 1.16
Engagement of the ATR-dependent DNA damage response at the human papillomavirus 18 replication centers during the initial amplification. J Virol (2012) 1.14
Transcriptional activation of several heterologous promoters by the E6 protein of human papillomavirus type 16. J Virol (1992) 1.14
Using an immortalized cell line to study the HPV life cycle in organotypic "raft" cultures. Methods Mol Med (2005) 1.13
Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis (2006) 1.11
Roles of the E6 and E7 proteins in the life cycle of low-risk human papillomavirus type 11. J Virol (2004) 1.11
Stabilization of HPV16 E6 protein by PDZ proteins, and potential implications for genome maintenance. Virology (2011) 1.02
Long-term effect of interferon on keratinocytes that maintain human papillomavirus type 31. J Virol (2002) 1.02
Interaction between the HPV-16 E2 transcriptional activator and p53. Oncogene (1999) 1.02
The full-length E1E4 protein of human papillomavirus type 18 modulates differentiation-dependent viral DNA amplification and late gene expression. Virology (2007) 1.01
Human papillomavirus type 16 E6 proteins with glycine substitution for cysteine in the metal-binding motif. Virology (1991) 0.99
Human papillomavirus E6 proteins mediate resistance to interferon-induced growth arrest through inhibition of p53 acetylation. J Virol (2007) 0.95
The E1 protein of human papillomavirus type 16 is dispensable for maintenance replication of the viral genome. J Virol (2012) 0.95
p53 protein is a suppressor of papillomavirus DNA amplificational replication. J Virol (1998) 0.93
Reversal of p53-induced cell-cycle arrest. Mol Carcinog (1999) 0.93
The role of the human papillomavirus type 18 E7 oncoprotein during the complete viral life cycle. Virology (2005) 0.92
E1 protein of bovine papillomavirus 1 is not required for the maintenance of viral plasmid DNA replication. Virology (2002) 0.92
Transcription-modulatory activity of full-length E6 and E6*I proteins of human papillomavirus type 16. Virology (1994) 0.89
The human papillomavirus type 11 E1/\E4 protein is not essential for viral genome amplification. Virology (2006) 0.88
HPV-18 E6 mutants reveal p53 modulation of viral DNA amplification in organotypic cultures. Proc Natl Acad Sci U S A (2013) 0.85
P53 represses human papillomavirus type 16 DNA replication via the viral E2 protein. Virol J (2008) 0.84
Analysis of the roles of E6 binding to E6TP1 and nuclear localization in the human papillomavirus type 31 life cycle. Virology (2006) 0.84
Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res (2007) 2.93
Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res (2003) 2.32
Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog (2009) 1.94
The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6's induction of epithelial hyperplasia in vivo. J Virol (2003) 1.91
Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res (2013) 1.87
Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet (2004) 1.74
Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation. Proc Natl Acad Sci U S A (2005) 1.72
Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci U S A (2006) 1.57
The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle. J Virol (2005) 1.53
Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci U S A (2005) 1.50
Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle. J Virol (2003) 1.49
Recapitulation of the effects of the human papillomavirus type 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in vivo. Mol Cell Biol (2003) 1.43
The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res (2007) 1.39
Methylation patterns of papillomavirus DNA, its influence on E2 function, and implications in viral infection. J Virol (2003) 1.37
Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogene. Cancer Res (2005) 1.34
Estrogen and ERalpha: culprits in cervical cancer? Trends Endocrinol Metab (2010) 1.33
Human papillomavirus type 16 E1circumflexE4 contributes to multiple facets of the papillomavirus life cycle. J Virol (2005) 1.32
The human papillomavirus type 16 E7 oncoprotein activates the Fanconi anemia (FA) pathway and causes accelerated chromosomal instability in FA cells. J Virol (2007) 1.29
Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors. J Natl Cancer Inst (2004) 1.28
Requirement of PDZ-containing proteins for cell cycle regulation and differentiation in the mouse lens epithelium. Mol Cell Biol (2003) 1.27
Merkel cell polyomavirus: a newly discovered human virus with oncogenic potential. Virology (2013) 1.27
Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer. Cancer Res (2010) 1.26
Critical roles for non-pRb targets of human papillomavirus type 16 E7 in cervical carcinogenesis. Cancer Res (2006) 1.21
Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer. Cancer Res (2008) 1.21
Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts. Clin Cancer Res (2012) 1.20
Interactions with pocket proteins contribute to the role of human papillomavirus type 16 E7 in the papillomavirus life cycle. J Virol (2005) 1.16
DEK proto-oncogene expression interferes with the normal epithelial differentiation program. Am J Pathol (2008) 1.15
Two distinct activities contribute to human papillomavirus 16 E6's oncogenic potential. Cancer Res (2005) 1.15
A mutant of human papillomavirus type 16 E6 deficient in binding alpha-helix partners displays reduced oncogenic potential in vivo. J Virol (2002) 1.15
Role of Rb-dependent and Rb-independent functions of papillomavirus E7 oncogene in head and neck cancer. Cancer Res (2007) 1.13
Human papillomavirus type 16 E1 E4-induced G2 arrest is associated with cytoplasmic retention of active Cdk1/cyclin B1 complexes. J Virol (2005) 1.10
Stable replication of papillomavirus genomes in Saccharomyces cerevisiae. J Virol (2002) 1.07
p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers. Cancer Res (2008) 1.06
Key Characteristics of Carcinogens as a Basis for Organizing Data on Mechanisms of Carcinogenesis. Environ Health Perspect (2015) 1.05
Examination of the pRb-dependent and pRb-independent functions of E7 in vivo. J Virol (2005) 1.05
Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists. Proc Natl Acad Sci U S A (2009) 1.04
Persistence of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene. Cancer Res (2009) 1.04
Effects of cellular differentiation, chromosomal integration and 5-aza-2'-deoxycytidine treatment on human papillomavirus-16 DNA methylation in cultured cell lines. Virology (2008) 1.04
A role for HPV16 E5 in cervical carcinogenesis. Cancer Res (2010) 1.03
Human papillomavirus E7 oncoprotein overrides the tumor suppressor activity of p21Cip1 in cervical carcinogenesis. Cancer Res (2009) 1.02
The fanconi anemia pathway limits human papillomavirus replication. J Virol (2012) 1.01
Epigenetics of human papillomaviruses. Virology (2013) 1.00
Human papillomavirus type 16 E6 and E7 oncoproteins act synergistically to cause head and neck cancer in mice. Virology (2010) 1.00
Phosphorylation of p53 at serine 37 is important for transcriptional activity and regulation in response to DNA damage. Oncogene (2004) 1.00
Requirement for stromal estrogen receptor alpha in cervical neoplasia. Horm Cancer (2012) 1.00
Human papillomavirus 16 E5 oncogene contributes to two stages of skin carcinogenesis. Cancer Res (2007) 0.98
Rapamycin inhibits anal carcinogenesis in two preclinical animal models. Cancer Prev Res (Phila) (2010) 0.96
A mouse model for human anal cancer. Cancer Prev Res (Phila) (2010) 0.96
Prevalence of human papillomavirus in oropharyngeal squamous cell carcinoma in the United States across time. Chem Res Toxicol (2014) 0.96
Human papillomavirus 16 E6 variants differ in their dysregulation of human keratinocyte differentiation and apoptosis. Virology (2008) 0.95
Inhibition of gamma secretase blocks HPV infection. Virology (2010) 0.94
Identification of cis-acting elements that mediate the replication and maintenance of human papillomavirus type 16 genomes in Saccharomyces cerevisiae. J Virol (2005) 0.94
Rare human papillomavirus 16 E6 variants reveal significant oncogenic potential. Mol Cancer (2011) 0.93
Inactivating all three rb family pocket proteins is insufficient to initiate cervical cancer. Cancer Res (2012) 0.93
Cervical cancers require the continuous expression of the human papillomavirus type 16 E7 oncoprotein even in the presence of the viral E6 oncoprotein. Cancer Res (2012) 0.92
E1 protein of bovine papillomavirus 1 is not required for the maintenance of viral plasmid DNA replication. Virology (2002) 0.92
Induction of promyelocytic leukemia (PML) oncogenic domains (PODs) by papillomavirus. Virology (2007) 0.91
Down-regulation of transforming growth factor-beta type II receptor (TGF-betaRII) protein and mRNA expression in cervical cancer. Mol Cancer (2008) 0.91
E6-associated protein is required for human papillomavirus type 16 E6 to cause cervical cancer in mice. Cancer Res (2010) 0.90
High incidence of HPV-associated head and neck cancers in FA deficient mice is associated with E7's induction of DNA damage through its inactivation of pocket proteins. PLoS One (2013) 0.90
Pocket proteins suppress head and neck cancer. Cancer Res (2012) 0.89
E6 and E7 oncoproteins induce distinct patterns of chromosomal aneuploidy in skin tumors from transgenic mice. Cancer Res (2004) 0.89
Expression of a single, viral oncoprotein in skin epithelium is sufficient to recruit lymphocytes. PLoS One (2013) 0.89
Dominant role of HPV16 E7 in anal carcinogenesis. Virology (2011) 0.88
The E6 oncoprotein from HPV16 enhances the canonical Wnt/β-catenin pathway in skin epidermis in vivo. Mol Cancer Res (2011) 0.87
Use of an in vivo animal model for assessing the role of integrin α(6)β(4) and syndecan-1 in early steps in papillomavirus infection. Virology (2012) 0.87
IFN-κ, a novel type I IFN, is undetectable in HPV-positive human cervical keratinocytes. Lab Invest (2010) 0.84
Requirement for Dlgh-1 in planar cell polarity and skeletogenesis during vertebrate development. PLoS One (2013) 0.83
Prevalence of Human Papillomavirus in Oropharyngeal Cancer: A Systematic Review. Cancer J (2015) 0.83
Sonoporation delivery of monoclonal antibodies against human papillomavirus 16 E6 restores p53 expression in transformed cervical keratinocytes. PLoS One (2012) 0.83
The HPV16 oncogenes cause aberrant stem cell mobilization. Virology (2013) 0.81
Requirement of estrogen receptor alpha DNA-binding domain for HPV oncogene-induced cervical carcinogenesis in mice. Carcinogenesis (2013) 0.81
HUMAN PAPILLOMAVIRUS ASSOCIATION WITH HEAD AND NECK CANCERS: UNDERSTANDING VIRUS BIOLOGY AND USING IT IN THE DEVELOPMENT OF CANCER DIAGNOSTICS. Expert Opin Med Diagn (2008) 0.80
Gene expression analysis of interferon kappa in laser capture microdissected cervical epithelium. Anal Biochem (2008) 0.80
Gene expression profile regulated by the HPV16 E7 oncoprotein and estradiol in cervical tissue. Virology (2013) 0.80
TGFβ signaling regulates lipogenesis in human sebaceous glands cells. BMC Dermatol (2013) 0.79
Papillomavirus E6 oncoprotein up-regulates occludin and ZO-2 expression in ovariectomized mice epidermis. Exp Cell Res (2013) 0.78
Novel antivirals inhibit early steps in HPV infection. Antiviral Res (2011) 0.77
The interwoven story of the small DNA tumor viruses. Virology (2009) 0.75
Characterization of interactions between transcription factors and a regulatory region spanning nt -320 to -281 of the HIV-1 LTR in T-lymphoid and non-T-lymphoid cells. J Biomed Sci (2002) 0.75